Skip to main
RVPH

Reviva Pharmaceuticals (RVPH) Stock Forecast & Price Target

Reviva Pharmaceuticals (RVPH) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Reviva Pharma is a late-stage pharmaceutical company with a promising pipeline and innovative technology platform that could potentially lead to new medicines for various diseases. Key things to monitor include clinical progress for the company's lead asset, brilaroxazine, potential regulatory interactions, and financing activity. The company is currently rated as a Buy with a price target of $2 per share, based on a discounted cash flow (DCF) valuation and other key assumptions. However, there are risks involved, including potential delays in development and approval, potential negative trial results, and potential dilution.

Bears say

Reviva Pharma is a development-stage pharmaceutical company with a limited product pipeline and significant risk factors, such as clinical, regulatory, financial, legal, and intellectual property risks. The company's lead drug candidate, brilaroxazine, has demonstrated potential benefits for the treatment of multiple psychiatric and inflammatory diseases, but its success is not guaranteed given its early-stage development and competition in these markets. Furthermore, the company will need to raise additional capital, likely through equity financing, which could result in share dilution for current shareholders. Combined with the current negative sentiment among investors, we believe that Reviva Pharma's stock may face significant challenges in the near term.

Reviva Pharmaceuticals (RVPH) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Reviva Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Reviva Pharmaceuticals (RVPH) Forecast

Analysts have given Reviva Pharmaceuticals (RVPH) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Reviva Pharmaceuticals (RVPH) has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Reviva Pharmaceuticals (RVPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.